Breaking World Pharma News

Preventing 'cytokine storm' may ease severe COVID-19 symptoms

For some COVID-19 patients, the body's immune response may be as destructive as the virus that causes the disease. The persistent high fevers, severe respiratory distress, and lung damage seen in some critically ill patients are all signs of an immune system in overdrive.

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine widely accessible around the world in an equitable manner.

Global regulators commit to cooperate on observational research in the context of COVID-19

Regulators from around the world have agreed three priority areas for cooperation on observational research during COVID-19. They will collaborate on pregnancy research, on medicines used in clinical practice and on vaccine safety and effectiveness monitoring.

Official COVID-19 deaths underestimate the full impact of the pandemic

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December 2019. However, only approximately half of all deaths recorded this spring were classified as confirmed COVID-19 deaths. The study shows that the health impacts of the COVID-19 pandemic may go far beyond official COVID-19 death counts.

Local climate unlikely to drive the early COVID-19 pandemic

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal Science.

The researchers found that the vast number of people still vulnerable to the strain of coronavirus causing the pandemic - SARS-CoV-2 - and the speed at which the pathogen spreads means that climate conditions are only likely to make a dent in the current rate of infection.

Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially reduce the risk of death from the most serious complication of Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection.

Antibody neutralizes SARS and COVID-19 coronaviruses

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

The antibody, called S309, is now on a fast-track development and testing path at Vir Biotechnology in the next step toward possible clinical trials.

Johnson & Johnson announces collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of vaccine efficacy than conventional tests for neutralizing antibodies. The current coronavirus pandemic, together with episodic outbreaks of infections caused by other pathogenic viruses, represent a growing threat to societies around the world, especially when effective vaccines are either lacking altogether or are in short supply.

Arthritis drug may improve respiratory function in some patients with severe COVID-19

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients with severe coronavirus disease 2019 (COVID-19). The eight patients also had a condition called secondary hemophagocytic lymphohistiocytosis (sHLH), which is characterized by overactivation of the immune system and organ failure.

WORLDPHARMANEWS

Breaking World Pharma News

Preventing 'cytokine storm' may ease severe COVID-19 symptoms

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine

Global regulators commit to cooperate on observational research in the context of COVID-19

Official COVID-19 deaths underestimate the full impact of the pandemic

Local climate unlikely to drive the early COVID-19 pandemic

Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19

Antibody neutralizes SARS and COVID-19 coronaviruses

Johnson & Johnson announces collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate

Early indicators of vaccine efficacy

Arthritis drug may improve respiratory function in some patients with severe COVID-19

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs